Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Capital Expenditures (2023 - 2025)

Kura Oncology (KURA) has disclosed Capital Expenditures for 3 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 1139.52% to $4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.6 million through Dec 2025, up 1306.36% year-over-year, with the annual reading at $6.6 million for FY2025, 1306.36% up from the prior year.
  • Capital Expenditures for Q4 2025 was $4.6 million at Kura Oncology, up from $277000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $4.6 million in Q4 2025, with the low at $16000.0 in Q4 2023.
  • Average Capital Expenditures over 3 years is $661636.4, with a median of $96000.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures tumbled 83.33% in 2024, then skyrocketed 9012.5% in 2025.
  • Over 3 years, Capital Expenditures stood at $16000.0 in 2023, then soared by 2225.0% to $372000.0 in 2024, then soared by 1139.52% to $4.6 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $4.6 million, $277000.0, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.